Tag
The company's CEO stepped down on Monday
We'd pay a lot more if it wasn’t for generics, which amount to as much as 85% of what we take.
Valeant and a handful other firms may ditch a model that's come under fire.
A new report suggests drug makers are profiting from the waste.
Combined, Shire and Baxalta expect 65 percent of total revenue to come from rare disease treatments.
Assistance programs are also marketing tools that can raise overall costs.
